First Patient Dosed in Gamida-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Bristol Myers Squibb and 2seventy bio Show Topline Results from KarMMa-3 Trial

Pfizer reports positive top-line results from Phase 3 study of IPD vaccine candidate

AstraZeneca granted US approval of Enhertu for HER2-mutant NSCLC

MaaT Pharma Receives US FDA Update on Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease

argenx announces EU approval of VYVGART for treatment of gMG

Roche's VENTANA MMR RxDx Panel receives US FDA label expansion approval

Peel Therapeutics starts first-in-human clinical study of PEEL-224 in patients with advanced solid tumours

Abionic Receives IVDR Certification for Its Predictive Ultra-Rapid Sepsis Test Allowing the Management of Antibiotic Administration

Pfizer, Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Relmada Therapeutics REL-1017 receives US FDA Fast Track designation to treat major depressive disorder

TransMed7 Shows First Clinical Use of SpeedBird Breast Biopsy Devices for Commercial Launch

Reata Pharmaceuticals Notified of a Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich's Ataxia

Ferring Announces US FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic